Hydergine LC belongs to the group of medicines known as ergot alkaloids. It is used to treat some mood, behavior, or other problems that may be due to changes in the brain from Alzheimer's disease or multiple small strokes.
Hydergine LC is different from other ergot alkaloids such as ergotamine and methysergide. It is not useful for treating migraine headache. The exact way Hydergine LC acts on the body is not known.
Hydergine LC is available only with your doctor's prescription.
Hydergine LC indications
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
Use Hydergine LC as directed by your doctor. Check the label on the medicine for exact dosing instructions. Check the label on the medicine for exact dosing instructions.
Do not eat, drink, or smoke while you take Hydergine LC.
Place Hydergine LC beneath your tongue and allow it to dissolve completely.
Do not swallow, crush, or chew Hydergine LC.
If you miss a dose of Hydergine LC, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once. If you miss more than 1 dose, contact your doctor.
Ask your health care provider any questions you may have about how to use Hydergine LC.
Uses of Hydergine LC in details
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
This medication is used to treat mild problems with mood, memory, concentration, or behavior in the elderly. It is believed to increase blood flow to the brain. It is a combination of 3 ergot alkaloids.
How to use H.E.A.
Take this medication by mouth, usually 3 times daily or as directed by your doctor.
Use this medication regularly to get the most benefit from it. To help you remember, take it at the same times each day.
It may take several weeks before you see any improvement from the medication. Tell your doctor if your condition persists or worsens.
Hydergine LC description
sponsored
Hydergine LC is a dihydrogenated ergot (Claviceps purpurea) derivative alkaloid used as a vasodilator agent. Hydergine LC is the only vasodilator that has shown mild benefits in the treatment of vascular dementia.
Hydergine LC dosage
Usual Adult Dose for Dementia
1 mg orally 3 times a day
Comments:
-The decision to treat an individual with an ill-defined decline in mental capacity may result in missing underlying conditions that could be reversible and treatable; great care should be exercised to exclude delirium secondary to systemic disease, primary neurological disease, or primary disturbance of mood as possible conditions prior to treatment.
-Continued clinical evaluation is necessary during treatment as the patient's condition may evolve sufficiently to allow for a specific diagnosis and specific alternative treatment.
Use: Symptomatic relief of an idiopathic decline in mental capacity effecting self-care, mood, motivation, cognitive and interpersonal skills.
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Precautions
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
-Take orally 3 times a day
Storage requirements: Protect from light
General:
-As treatment with this drug means target symptoms are of unknown etiology, careful diagnosis should be attempted prior to prescribing.
-Once therapy begins, alleviation of symptoms may not be observed for 3 to 4 weeks.
-Modest efficacy was shown on the SCAG (Sandoz Clinical Assessment-Geriatric) scale including improvements to mental alertness, confusion, recent memory, orientation, emotional lability, self-care, depression, anxiety/fears, cooperation, sociability, appetite, dizziness, fatigue, bothersome (ness), and overall impression of clinical status at 12-weeks.
Monitoring:
-Monitor for reversible and treatable conditions
-Continually assess and rate improvements to ensure any initial benefit persists with time.
Patient advice:
-Transient nausea and gastric disturbances may occur.
-This drug does not possess the vasoconstrictor properties of natural ergot alkaloids.
Antihepaciviral Combination Products: May increase the serum concentration of Ergot Derivatives. Avoid combination
Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Monitor therapy
Beta-Blockers: May enhance the vasoconstricting effect of Ergot Derivatives. Consider therapy modification
Chloroprocaine: May enhance the hypertensive effect of Ergot Derivatives. Monitor therapy
Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Monitor therapy
Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Avoid combination
CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors). Monitor therapy
CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors). Management: Consider avoiding this combination. Some combinations are specifically contraindicated by manufacturers; others may have recommended dose adjustments. If combined, monitor for increased substrate effects. Consider therapy modification
Duvelisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Monitor therapy
Erdafitinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Monitor therapy
Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Monitor therapy
Fosnetupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Monitor therapy
Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Avoid combination
Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Avoid combination
Itraconazole: May increase the serum concentration of Hydergine LC. Avoid combination
Ketoconazole (Systemic): May increase the serum concentration of Hydergine LC. Avoid combination
Larotrectinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Monitor therapy
Letermovir: May increase the serum concentration of Ergot Derivatives. Avoid combination
Lorcaserin (Withdrawn From US Market): May enhance the adverse/toxic effect of Ergot Derivatives. Specifically, use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin (Withdrawn From US Market) may enhance the serotonergic effect of Ergot Derivatives. This could result in serotonin syndrome. Avoid combination
Macrolide Antibiotics: May increase the serum concentration of Ergot Derivatives. Cabergoline and Clarithromycin may interact, see specific monograph for full details. Exceptions: Azithromycin (Systemic); Fidaxomicin; Spiramycin. Avoid combination
MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus. Consider therapy modification
Nefazodone: Ergot Derivatives may enhance the serotonergic effect of Nefazodone. This could result in serotonin syndrome. Nefazodone may increase the serum concentration of Ergot Derivatives. Avoid combination
Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Monitor therapy
Nitroglycerin: Ergot Derivatives may diminish the vasodilatory effect of Nitroglycerin. This is of particular concern in patients being treated for angina. Nitroglycerin may increase the serum concentration of Ergot Derivatives. Avoid combination
Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Monitor therapy
Posaconazole: May increase the serum concentration of Hydergine LC. Avoid combination
Protease Inhibitors: May increase the serum concentration of Ergot Derivatives. Avoid combination
Reboxetine: May enhance the hypertensive effect of Ergot Derivatives. Monitor therapy
Roxithromycin: May increase the serum concentration of Ergot Derivatives. Avoid combination
Serotonergic Agents (High Risk): Ergot Derivatives may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Exceptions: Nefazodone. Monitor therapy
Serotonin 5-HT1D Receptor Agonists (Triptans): Ergot Derivatives may enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists (Triptans). Serotonin 5-HT1D Receptor Agonists (Triptans) may enhance the vasoconstricting effect of Ergot Derivatives. Avoid combination
Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Monitor therapy
Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity. Any CYP3A4 substrate used with stiripentol requires closer monitoring. Consider therapy modification
Voriconazole: May increase the serum concentration of Hydergine LC. Avoid combination
Applies to Hydergine LC: capsule liquid filled, solution, tablet
In addition to its needed effects, some unwanted effects may be caused by Hydergine LC (the active ingredient contained in Hydergine LC LC). In the event that any of these side effects do occur, they may require medical attention.
Severity: Moderate
If any of the following side effects occur while taking Hydergine LC, check with your doctor or nurse as soon as possible:
Less common or rare:
Dizziness or lightheadedness when getting up from a lying or sitting position
drowsiness
skin rash
slow pulse
Signs and symptoms of overdose
Blurred vision
dizziness
fainting
flushing
headache
loss of appetite
nausea or vomiting
stomach cramps
stuffy nose
Minor Side Effects
Some of the side effects that can occur with Hydergine LC may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:
Hydergine LC® (Hydergine LC) preparations are contraindicated in individuals who have previously shown hypersensitivity to the drug. Hydergine LC® (Hydergine LC) preparations are also contraindicated in patients who have psychosis, acute or chronic, regardless of etiology.
The results of a survey conducted on ndrugs.com for Hydergine LC are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Hydergine LC. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
User reports
Consumer reported useful
No survey data has been collected yet
Consumer reported price estimates
No survey data has been collected yet
Consumer reported time for results
No survey data has been collected yet
1 consumer reported age
Users
%
30-45
1
100.0%
Consumer reviews
There are no reviews yet. Be the first to write one!
Information checked by Dr. Sachin Kumar, MD Pharmacology